Introduction
Chronic kidney disease (CKD) is an independent risk factor for stroke 1 and affects 8% to 16% of the global population. 2 Stroke is a leading cause of disability and death in CKD and dialysis patients with nonvalvular atrial fibrillation (NVAF). NVAF is associated with kidney disease 3 having an incidence of 2.7 per 100 patient-years and prevalence of 11.6% in dialysis with heterogeneity among studies due to different populations, definitions, and ascertainment of NVAF. NVAF is a key contributing factor 4 to the increased risk of stroke in CKD and dialysis patients with rates of stroke varying according to the degree of kidney dysfunction as well as the definition of stroke (ischemic vs hemorrhagic) and its method of ascertainment. [5] [6] [7] There is controversy over the management of stroke and systemic embolism risk in CKD and dialysis patients with NVAF due to the uncertain efficacy and safety of oral anticoagulation (OAC) 8, 9 due to an altered responsiveness to vitamin K antagonists (VKAs), 10, 11 platelet dysfunction, and an increased risk of major bleeding. [12] [13] [14] Not surprisingly, kidney dysfunction is an independent predictor of bleeding in NVAF patients treated with OAC. [15] [16] [17] Left atrial appendage occlusion devices (LAAODs) are a novel intervention that has been shown to be noninferior to VKAs for stroke and systemic embolism prevention in NVAF in the general population. The WATCHMAN LAAOD is associated with more ischemic strokes but less hemorrhagic strokes compared to warfarin with procedural risks including ischemic stroke. 18, 19 Apixaban is a factor Xa inhibitor that has been shown to be superior to warfarin for stroke and systemic embolism prevention in NVAF in the general population 20 but randomized trial evidence does not exist for individuals with a creatinine clearance (CrCl) <25 mL/min, including those receiving dialysis.
We surveyed Canadian nephrologists to elicit their views regarding stroke and systemic embolism prevention therapies in CKD and dialysis patients with NVAF and their willingness to let their patients participate in randomized controlled trials (RCTs) of novel alternative therapies to warfarin including LAAODs and apixaban.
Methods

Survey Design and Target Audience
The survey was designed by 2 of the authors (David Collister, MW) and piloted on 2 nephrologists (KSB, CR) and 2 cardiologists (JH, David Conen) for clinical sensibility and comprehension. Its final version was piloted on 4 nephrologists for functionality on the survey platform surveymonkey.com (see the appendix). The survey was circulated to Canadian Society of Nephrology members on April 12, 2017 (n = 251) with the target demographic including Canadian nephrologists actively treating adult CKD (including kidney transplant recipients with estimated glomerular filtration rate [eGFR] <30 mL/min/1.73m 2 ) and dialysis patients excluding trainees, allied health members, and researchers. Follow-up reminders were sent 1 and 2 weeks later with subsequent individualized email reminders. Responses were anonymous, and all answers required to all questions. Ethics approval was not obtained given waived consent for surveys at our institution.
Previous Experiences With Novel Therapies
The first section of the survey elicited prior experiences treating CKD or dialysis patients with NVAF with the WATCHMAN LAAOD or apixaban. It provided background information regarding these interventions in the general population including the PROTECT-AF 18 and PREVAIL 19 RCTs, an individual patient-level meta-analysis of these trials and their respective registries 21 in addition to ARISTOTLE 20 and its CKD subgroup analysis 22 and an apixaban hemodialysis pharmacokinetic study. 23 Demographic information including the number of years in independent practice (in 5-year increments) and work environment (university, community with university affiliation, university, other) was collected.
Views Regarding for Stroke and Systemic Embolism Prevention
The second section of the survey consisted of 4 cases, of which 2 were randomly assigned to each respondent. Each case involved a 65-year-old Caucasian man on intermittent hemodialysis with NVAF (representative of a typical Canadian dialysis patient eligible for participation in potential clinical trials) but with varying CHADS2 24 (congestive heart failure, hypertension, age >65, diabetes mellitus, stroke) and HASBLED 15 (hypertension, abnormal renal/liver function, stroke, bleeding tendency or predisposition, labile INR, age >65, drugs [eg, concomitant ASA or NSAIDs] or alcohol) scores ( Table 1 ). Risk prediction tools and absolute risks were not explicitly presented.
Respondents were then asked a series of questions regarding the management of each case with a response option of a Likert scale ranging from 1 to 8 with 1 being definitely would not and 8 being definitely would for the likelihood of 
Note. For CHADS2, C = congestive heart failure, H = hypertension, A = age >65, D = diabetes mellitus, S = stroke; for HASBLED, H = hypertension, A = abnormal renal/liver function, S = stroke, B = bleeding tendency or predisposition, L = labile INR, E = age >65, D = drugs (antiplatelets or NSAID); INR = international normalized ratio; NSAID = nonsteroidal anti-inflammatory drug.
recommending (1) warfarin, (2) the WATCHMAN LAAOD, (3) apixaban and if they would consider enrolling the patient into a RCT comparing, (4) the WATCHMAN LAAOD with warfarin, or (5) apixaban with warfarin. Last, respondents were asked whether they utilized risk prediction tools to classify stroke and systemic embolism risks as well as bleeding risks when deciding whether or not to prescribe an OAC in their CKD or dialysis patients with NVAF.
Physician Minimal Clinically Important Difference (MCID)
Physician were asked how many major bleeding episodes requiring hospitalization would they would accept to prevent one ischemic stroke with disability with responses of 1, 2, 3, 4, 5 and greater than 5.
Statistical Analysis
A complete case analysis was performed given that responses were required for all questions to progress through the survey. Descriptive statistics were performed to characterize survey respondents. Multilevel multivariable linear regression (cases clustered in physicians) was performed to determine independent predictors of the likelihood of clinical decisions for warfarin, LAAOD, and apixaban. All statistical tests were performed at a P < .05 level of significance. All analyses were performed using STATA (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP).
Results
Respondents
A total of 110 responses were received (43.8% response rate) but only 91 complete surveys (36.3% response rate) were analyzed. The characteristics of survey participants are shown in Table 2 . The majority of participants did not have any previous clinical experience with the use of LAAODs (91.2%) or apixaban (86.8%) in their dialysis patients. Most (85.7%) used CHADS2 score or an equivalent tool for stroke/systemic embolism risk prediction and 46.2% used HASBLED score or equivalent tool for bleeding risk prediction.
Stroke and Systemic Embolism Prevention Therapies
Physician number of years in practice, physician practice setting, use of CHADS2 or HASBLED as risk prediction tools, and physician MCID were not statistically significant predictors of recommending stroke and systemic embolism preventive therapies (not shown). The interaction between stroke and bleeding risks was the only statistically significant predictor of treatment recommendations and was the only variable included in the final multilevel linear regression model (not shown).
Likelihoods by Treatments
The likelihood of recommending treatment with warfarin, a LAAOD, or apixaban for each case (within-group comparisons with warfarin as the reference) is shown in Figure 1 . There was heterogeneity in recommendations for warfarin, LAAOD, and apixaban therapy (see Supplemental Figures 1,  2, 3 ). In case 1 (CHADS2 = 1, HASBLED = 2), apixaban was less likely to be recommended than warfarin (P = .033). In case 2 (CHADS2 = 1, HASBLED = 4), a LAAOD was more likely to be recommended than warfarin (P = .000). In case 3 (CHADS2 = 5, HASBLED = 3), both a LAAOD and apixaban were less likely to be recommended than warfarin (P = .008, P = .000, respectively). In case 4 (CHADS2 = 5, HASBLED = 5), apixaban was less likely to be recommended than warfarin (P = .001).
Likelihoods by Stroke/Systemic Embolism and Bleeding Risks
The likelihood of recommending therapy with warfarin, a LAAOD, or apixaban across cases (between-group comparisons with case 1 as the reference) is shown in Figure 2 . With regard to warfarin, case 2 (CHADS2 = 1, HASBLED = 4) was less likely (P = 0) and case 3 (CHADS2 = 3, HASBLED = 5) was more likely (P = 0) to be recommended warfarin therapy. There was no difference between cases in the likelihood of recommending a LAAOD with overall uncertainty (clustering of responses between 4 and 5 on the Likert scale). With regard to apixaban, it was not likely to be recommended in all 4 cases (all 95% confidence interval [CI] upper limits less than 4.5) but it was the least likely to be recommended in case 2 (CHADS2 = 1, HASBLED = 4, P = .001).
MCID
The physician MCID for the number of major bleeds they would accept to prevent one nonfatal disabling ischemic stroke was a mean of 2.33 (SD = 1.21).
Participation in Future RCTs
Clinicians were interested in allowing their patients to participate in RCTs of LAAOD or apixaban (Supplemental Figures 4 and 5 ).
Discussion
In this survey of Canadian nephrologists to elicit practice patterns for stroke and systemic embolism prevention for NVAF in hemodialysis, we found heterogeneity in the likelihood of recommending warfarin, LAAOD, and apixaban across varying stroke/systemic embolism as well as bleeding risks. Warfarin was more likely to be recommended in individuals at high stroke/systemic embolism risk and low bleeding risk (case 3, CHADS2 = 5, HASBLED = 3) and less likely to be recommended in individuals at moderate stroke/ systemic embolism risk and high bleeding risk (case 2, CHADS2 = 1, HASBLED = 4). There was uncertainty regarding recommending LAAOD that did not vary by stroke/systemic embolism or bleeding risks and apixaban was not likely to be recommended in any case. However, nephrologists were willing to enroll their dialysis patients in RCTs comparing both LAAOD and apixaban with warfarin to formally evaluate the safety and efficacy of these novel therapies.
Our finding of heterogeneity of OAC decision making for NVAF for stroke and systemic embolism prevention depending on perceived stroke and bleeding risks in CKD and dialysis is supported by previous studies. A survey of Canadian nephrologists in 2013 consisting of 6 hypothetical scenarios involving CKD and dialysis patients with varying stroke and bleeding risks demonstrated uncertainty regarding the initiation of OAC for NVAF ranging from 16.1% to 48.2% depending on the scenario 25 but did not include novel therapies. A survey of Italian nephrologists in 2010 assessing practice patterns of OAC for NVAF in dialysis patients demonstrated that comorbidities were a driver of nonprescription of OAC (22.4% of cases) and that this factor was more important than both previous major bleeding (8.3%) and falls (1.3%) when recommending warfarin. 26 In the Dialysis Outcomes and Practice Patterns Study, OAC use ranged from 2% in Germany to 26% in the United States to 37% in Canada 27 suggesting regional variation perhaps related to comorbidities or differing values and preferences regarding stroke/systemic embolism prevention and bleeding internationally as well as absence of randomized trials.
Our study demonstrated that stroke risk prediction tools are widely used in CKD and dialysis given their accuracy 28 but bleeding risk prediction tools are employed less often, perhaps due to the belief that all patients with kidney dysfunction are considered at high risk of bleeding regardless of other risk factors. The interaction between stroke and bleeding risks, however, appears to guide physicians when deciding on therapeutic recommendations but how physicians actually incorporate their own as well as their patients' beliefs regarding trade-offs between outcomes remains uncertain. Individualization of therapy is needed that not only acknowledges the uncertainty of the efficacy of OAC in dialysis but also the challenge in determining risks due to their variations across populations 29 and the problematic correlation between stroke and bleeding risks. This is the first study to report a MCID for bleeding/ stroke trade-offs for warfarin in the CKD or dialysis population. Patient and physician MCID for both ASA and warfarin for NVAF stroke prevention have previously been shown to be greater for patients than physicians at 17.4 (SD = 7.1) versus 10.3 (SD = 6.1) (warfarin) and 14.7 (SD = 8.5) versus 6.7 (SD = 6.2) (ASA) episodes of excess bleeding in 100 patients over 2 years. 30 Another study demonstrated variability in physician and patient MCID with clustering of less than 10 bleeds for both groups but also greater than 35 for a group of patients with health utilities (the perceived value of a health state ranging from death [0] to full health [100]) of major stroke and bleeding states being 21.5 (SD = 15.9) and 44.0 (SD = 19.9), respectively. 30 Our physician MCID of 2.33 (SD = 1.21) is different from that reported in general population and is likely due to considerations unique to bleeding in CKD and dialysis patients including the risk of acute kidney injury (AKI)/progression of CKD as well as that of red blood cell transfusions and the development of donor-specific antibodies in addition to other adverse clinical outcomes. However, it should be recognized that our study did not utilize any formal methodologies such as probability trade-offs to determine a physician MCID.
The WATCHMAN LAAOD as an alternative to OAC for stroke and systemic embolism prevention in NVAF is a promising therapy for individuals at significant bleeding risk as it avoids long-term OAC. A systematic review and meta-analysis of 832 RCTs and 1145 registry patients compared with 382 VKA controls showed that the WATCHMAN LAAOD was noninferior to VKA when considering a composite efficacy endpoint but with an overall increase in ischemic strokes but decrease in hemorrhagic strokes. 21 Direct oral anticoagulants (DOACs) have been shown to be safe and are likely effective in less advanced CKD (CrCl = 30-50 mL/min) with a pooled relative risk reduction of 0.64 (95% CI = 0.39-1.04) for stroke and systemic embolism and no statistically significant increase in bleeding in a meta-analysis of 8 RCTs of DOACs (including apixaban, rivaroxaban, dabigatran) versus VKAs. 31 However, limited evidence exists in CKD with a CrCl < 25 mL/min and dialysis with pharmacokinetic data for apixaban in hemodialysis showing negligible dialyzability. 32 Although no RCTs have evaluated the efficacy of the DOACs in patients with AF receiving dialysis, these agents are being increasingly prescribed in the dialysis population, particularly apixaban, which accounted for almost 11% of prescribed oral anticoagulants in American dialysis recipients. 33 A large observational study of almost 25 000 dialysis recipients in the United States demonstrated that apixaban had a similar risk of stroke/systemic thromboembolism as warfarin. 34 In subgroup analysis, the 5 mg twice a day dose of apixaban was noted to provide a statistically significant decrease in stroke risk versus warfarin (hazard ratio [HR] = 0.64; 95% CI = 0.42-0.97) as compared with the 2.5 mg twice a day dose (HR = 1.11; 95% CI = 0.82-1.50).
Enthusiasm for RCTs in this area has previously been identified in a survey of Canadian nephrologists where 67% of responders reporting they would enroll patients if already on a VKA and 82% if not already VKA into an RCT of VKA versus placebo. 25 AVKDIAL 35 is an unblinded multicenter RCT comparing VKA to no OAC in adult HD patients with AF and a CHADS2VASC score ≥2 at high risk of bleeding that has yet to start enrolling. Other RCTs include RENAL-AF 36 (apixaban vs VKA) and STOP-HARM 37 (LAAOD vs VKA) are ongoing.
The strengths of this study include its size, response rate, and design to limit bias by randomizing participants to cases. However, it does have its limitations. The survey population did not include cardiologists, hematologists, or other health care professionals that might be involved in shared decision making with dialysis patients with NVAF. However, given that nephrologists typically coordinate not only dialysis-specific care but also cardiovascular risk reduction, it is likely that our study sample is representative of current NVAF practice patterns in the Canadian hemodialysis population. We were unable to present all the different combinations of stroke/systemic embolism and bleeding risks but instead focused on 4 cases that dichotomized risk categories to explore treatment decisions where we detected variation without overwhelming respondents. Last, as with any survey, there is the potential for responder bias and likelihood scores for treatment decisions are not anchored to actual patient management so whether or not our results apply to clinical or research settings is unclear.
Conclusions
There is still uncertainty regarding the use of OAC for stroke and systemic embolism prevention in CKD and dialysis patients with NVAF. Alternatives to warfarin are needed given its unclear efficacy and potential for harm, with apixaban and LAAOD currently being evaluated as promising therapies. Nephrologists, their patients, and other subspecialists involved in the care of CKD and dialysis patients with NVAF anxiously await the results of these pivotal trials.
Ethics Approval and Consent to Participate
Ethics approval was not obtained, given waived consent for surveys at our institution.
